Latest News

Tiziana Life Sciences Interview to Air on Bloomberg Television US on the RedChip Money Report

26 February 2021

NEW YORK and LONDON - 26 February 2021 — Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced that an interview with it’s CEO, Dr Kunwar Shailubhai,...

Read more

PDMR DEALING

05 February 2021

NEW YORK and LONDON – February 5, 2021 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the...

Read more

APPOINTMENT OF DIRECTOR

05 February 2021

NEW YORK and LONDON – February 5, 2021 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the...

Read more

CEO Discusses COVID-19 Trial Data in Exclusive Interview

03 February 2021

NEW YORK and LONDON – February 3, 2021 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ:TLSA/LSE:TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced an interview with Dr. Kunwar...

Read more

Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil

02 February 2021

THIS ANNOUNCEMENT INCLUDES INSIDE INFORMATION

  • Since the anti-inflammatory effect of the nasally administered Foralumab is through the modulation of the immune system and not by directly targeting COVID-19, this therapeutic approach might also...

Read more

Tiziana files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission

27 January 2021

New York / London, January 27, 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces that it has filed a “universal” shelf...

Read more

Page 2 of 26 Previous Next